Eli Lilly Offers Expanded Access to New Obesity Medication
禮來公司擴大新一代減肥藥物的供應管道
更新於: 2026年8月8日 上午02:30
In a significant move for patients struggling with severe, treatment-resistant obesity, Eli Lilly has launched an 'expanded access' program for its experimental drug, retatrutide.
對於正與嚴重且具治療抗性之肥胖症搏鬥的患者而言，禮來公司(Eli Lilly)採取了一項重大舉措，針對其實驗性藥物 retatrutide 啟動了「擴大取得(expanded access)」計畫。
While the medication awaits official FDA approval—expected in early 2027—this new program offers a path for eligible individuals to receive treatment before it reaches the general market.
儘管該藥物尚待美國食品藥物管理局(FDA)正式批准（預計於2027年初取得），但這項新計畫為符合資格的個人提供了在藥物進入一般市場前接受治療的途徑。
Retatrutide is notable for being a 'triple agonist,' meaning it targets three different hormone receptors to manage metabolism, potentially offering higher efficacy than current double-agonist treatments.
Retatrutide 的特點在於它是一種「三重促效劑」，意即它透過鎖定三種不同的荷爾蒙受體來調節代謝，其效力可能優於現行的雙重促效劑療法。
Eligibility is strict, requiring patients to be at least 18 years old, to have failed other obesity therapies, and to have two or more serious health complications.
申請資格極為嚴格，要求患者必須年滿18歲，且其他肥胖治療無效，並患有兩項或以上嚴重的健康併發症。
Crucially, access is not requested by patients directly, but must be initiated by a physician and approved by the FDA and an institutional review board.
至關重要的是，該計畫並非由患者直接請求，而必須由醫師發起，並經由美國食品藥物管理局及機構審查委員會批准。
Meanwhile, Eli Lilly continues its broader strategy to improve obesity care, including Medicare price caps for its drug Zepbound and the ongoing use of its LillyDirect platform to help patients navigate access to medication.
同時，禮來公司持續推動其擴大肥胖症照護的更廣泛策略，包括針對旗下藥物 Zepbound 實施聯邦醫療保險(Medicare)價格上限，並持續運用 LillyDirect 平台協助患者取得藥物資訊。
This development marks a proactive step in addressing the urgent needs of the medical community.
此發展標誌著該公司在回應醫學界迫切需求上，所邁出的積極一步。
